Global Endothelin Antagonists Therapeutics Market, By Drugs (Ambrisentan, Bosentan, Macitentan, Others), Indication (Cardiovascular Diseases, Scleroderma and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Endothelin Antagonists Therapeutics Market Analysis and Size
Increasing adoption of unhealthy lifestyle such as consumption of junk food and lack of physical activity that further surges the risk of developing high blood pressure that results in the pulmonary arterial hypertension can act as a positive indication for the growth of the market. Several ongoing research targeted at producing highly specific and effective therapeutics for PAH primarily focuses on developing integrative medicines that combine traditional and experimental substances.
Data Bridge Market Research analyses a growth rate in the endothelin antagonists therapeutics market in the forecast period 2023-2030. The expected CAGR of endothelin antagonists therapeutics market is tend to be around 6% in the mentioned forecast period. The market is valued at USD 3.5 billion in 2022, and it would grow upto USD 5.58 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Endothelin Antagonists Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Ambrisentan, Bosentan, Macitentan, Others), Indication (Cardiovascular Diseases, Scleroderma and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Gilead Sciences, Inc (U.S.), Sun Pharmaceutical Industries Ltd (India), Lupin (India), Zydus Group (India), Endo International plc (Ireland), Mylan N.V (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sigmapharm Laboratories, LLC (U.S.), Alembic Pharmaceuticals Limited (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC (U.S.), AstraZeneca (U.K.), Johnsons & Johnsons Private limited (U.S.) and GSK Plc (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
Endothelin Antagonists Therapeutics Market Dynamics
Drivers
- Increasing Strategic Developments by Various Market Players
Market players are applying numerous strategic efforts to enlarge their market share. Product development and launches, partnerships, distribution network expansion, and mergers and acquisitions are all a part of this expansion. To obtain a competitive advantage and boost their industrial presence, several companies invest enormously in the development and sale of highly innovative products. Several pharmaceutical companies are trying to enter the market trend by launching various generic versions of pulmonary arterial hypertension medications. In the next few years, this is projected to increase the competition. For instance, Viatris Inc. was created by combining Mylan N.V. and Pfizer Inc.'s Upjohn Business in November 2020. Viatris has a huge portfolio of biosimilars, branded and sophisticated generics, and over-the-counter pharmaceuticals, which includes Revatio, a PAH medication.Thus, this factor boosts the market growth.
Opportunities
- Wide Usage in Chronic Diseases
The huge usage of endothelin antagonists therapeutics in preventing or controlling chronic diseases is assisting in increasing the market growth. For instance, the overall occurrence of hypertension among adults in India is around 30% with urban incidence of 34% and rural prevalence of 28%. In U.S., around 103 million adults have high blood pressure, as per the new statistics from the American Heart Association. This as a result, increases the demand for the market.
- Increasing Healthcare Expenditure And Government Support
With the increasing prevalence of cancer, the rising awareness for the disease and the related treatment is also expanding. Several government initiatives tend to provide better and more feasible treatments along with favourable reimbursement policies that are expected to increase the industry growth. Furthermore, growing acceptance of advanced therapies is estimated to drive the market.
Restraints/Challenges
- High Cost of Treatment
The increasing expenditure related with the medications hamper the market growth. Numerous genetic drugs cost high, and people in highly developing and underdeveloped countries cause the under treatment of several patients. This impedes the market growth.
This endothelin antagonists therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the endothelin antagonists therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Endothelin Antagonists Therapeutics Market Scope
The endothelin antagonists therapeutics market is segmented on the basis of drugs, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Ambrisentan
- Bosentan
- Macitentan
- Others
Indication
- Cardiovascular Diseases
- Scleroderma
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Endothelin Antagonists Therapeutics Market Regional Analysis/Insights
The endothelin antagonists therapeutics market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the endothelin antagonists therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for endothelin antagonists therapeutics market throughout the forecasted period because of the increased diagnosis rate, increasing awareness and development activities for endothelin based therapeutics. Furthermore, the increasing presence of refined clinical facilities and rise in better treatment seeking rates of patients suffering from the pulmonary arterial hypertension boost the market growth in this region.
Asia-Pacific dominates the market because of the healthy improvement in healthcare infrastructure and huge economic development. Also, the wide availability of generic version of the drugs at an affordable price range is greatly increasing the growth of the market in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Endothelin Antagonists Therapeutics Market Share Analysis
The endothelin antagonists therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to endothelin antagonists therapeutics market.
Key players operating in the endothelin antagonists therapeutics market include:
- Gilead Sciences, Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- Lupin (India)
- Zydus Group (India)
- Endo International plc (Ireland)
- Mylan N.V (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sigmapharm Laboratories, LLC (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC (U.S.)
- AstraZeneca (U.K.)
- Johnsons & Johnsons Private limited (U.S.)
- GSK Plc (U.K.)
SKU-